- Home
- CREV vs GNPX Comparison
CREV vs GNPX Comparison
Compare CREV & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- GNPX
- Stock Information
- Founded
- CREV 2007
- GNPX 2009
- Country
- CREV Ireland
- GNPX United States
- Employees
- CREV N/A
- GNPX N/A
- Industry
- CREV
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- GNPX Health Care
- Exchange
- CREV Nasdaq
- GNPX Nasdaq
- Market Cap
- CREV 6.0M
- GNPX 5.5M
- IPO Year
- CREV N/A
- GNPX 2018
- Fundamental
- Price
- CREV $4.16
- GNPX $0.23
- Analyst Decision
- CREV
- GNPX
- Analyst Count
- CREV 0
- GNPX 0
- Target Price
- CREV N/A
- GNPX N/A
- AVG Volume (30 Days)
- CREV 57.1K
- GNPX 13.6M
- Earning Date
- CREV 05-14-2025
- GNPX 08-14-2025
- Dividend Yield
- CREV N/A
- GNPX N/A
- EPS Growth
- CREV N/A
- GNPX N/A
- EPS
- CREV N/A
- GNPX N/A
- Revenue
- CREV $39,261,077.00
- GNPX N/A
- Revenue This Year
- CREV $40.76
- GNPX N/A
- Revenue Next Year
- CREV $86.18
- GNPX N/A
- P/E Ratio
- CREV N/A
- GNPX N/A
- Revenue Growth
- CREV 41.52
- GNPX N/A
- 52 Week Low
- CREV $2.00
- GNPX $0.14
- 52 Week High
- CREV $12.75
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- CREV 48.40
- GNPX 58.63
- Support Level
- CREV $3.72
- GNPX $0.14
- Resistance Level
- CREV $5.02
- GNPX $0.17
- Average True Range (ATR)
- CREV 0.38
- GNPX 0.03
- MACD
- CREV -0.04
- GNPX 0.01
- Stochastic Oscillator
- CREV 33.85
- GNPX 77.49
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.